Posts With Tag GLP-1 Agonists

Explore how aggressive pricing in GLP-1 weight-loss medications is disrupting Big Pharma's business models, impacting stocks and investor strategies in the health sector.

Tiziana Life Sciences LTD's 2025 foreign issuer report highlights findings on nasal anti-CD3 monoclonal antibody, addressing GLP-1 drug tolerability issues. Read more in Exhibit 99.1!